Improve drug development, change patients' life
G Protein Coupled Receptors (GPCRs) represent 35% of all approved modern drug targets and are a major part of the 200 US most profitable drugs. These proteins are the most successful drug targets to treat diseases like cancer, Parkinson’s or Alzheimer’s. Current drug screening assays targeting GPCRs are time consuming and require high investments in liquid handling robots. Current methods need four successive assays to decipher the drug’s mode of action; each one lasts several hours, potentially generates radioactive waste and prevents the use of patient cells (replaced by approximate model cells), thus leading to more challenging clinical trials approval, and impacting the time-to-market of new drugs. Our solution, SynScreen revolutionizes GPCR screening by drastically reducing the assay time from hours to minutes by combining 4 tests in a unique and simple assay.
5 assays in 1
Suitable for primary cells
Early stage signalisation detection
Suitable for all GPCRs
Results in 15 min
Sample storage at -80°
© Thamani Dahoun and Margaux Duchamp
Proud to be part of this innovative project !
GPCRs are membrane proteins representing approximately 4% of the human genome. They are constituted of seven helices forming a cavity where the specific molecules, called ligands, can enter and bind to the protein. In some ways, ligand act as keys unlocking the GPCR and then the extracellular signal can be transmitted across the plasma membrane which leads to intracellular responses (figure). Due to their ability to transmit a wide variety of extracellular signals such as photons, mechanical stress, hormones, growth factors, neurotransmitters, odors, to the intracellular compartment, they are involved in many central physiological processes and are among the most important therapeutic targets for different diseases.
© Thamani Dahoun